KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT (2016 - 2025)

Jazz Pharmaceuticals has reported EBT over the past 16 years, most recently at $208.5 million for Q4 2025.

  • Quarterly results put EBT at $208.5 million for Q4 2025, up 56.49% from a year ago — trailing twelve months through Dec 2025 was -$384.8 million (down 181.82% YoY), and the annual figure for FY2025 was -$627.9 million, down 233.49%.
  • EBT for Q4 2025 was $208.5 million at Jazz Pharmaceuticals, up from $9.0 million in the prior quarter.
  • Over the last five years, EBT for JAZZ hit a ceiling of $208.5 million in Q4 2025 and a floor of -$735.6 million in Q2 2025.
  • Median EBT over the past 5 years was $21.0 million (2022), compared with a mean of -$12.4 million.
  • Biggest five-year swings in EBT: tumbled 658.41% in 2022 and later soared 771.16% in 2023.
  • Jazz Pharmaceuticals' EBT stood at -$44.8 million in 2021, then tumbled by 658.41% to -$340.0 million in 2022, then surged by 118.1% to $61.5 million in 2023, then soared by 116.52% to $133.2 million in 2024, then skyrocketed by 56.49% to $208.5 million in 2025.
  • The last three reported values for EBT were $208.5 million (Q4 2025), $9.0 million (Q3 2025), and -$735.6 million (Q2 2025) per Business Quant data.